Cancers & treatments·Regimen libraryFirst line

THP (docetaxel + trastuzumab + pertuzumab)

Checked 2026-09-09

HER2-positive metastatic breast cancer first line, then HP maintenance

One cycle

every 21 days

21-day cycle, docetaxel 6 or more; HP until progressionIntravenous

Components

Drug	Dose	Route	Days
Docetaxel Cytotoxic chemotherapy (taxane)	75 mg/m²	IV	D1
Trastuzumab Monoclonal antibody (anti-HER2)	8 mg/kg loading then 6 mg/kg	IV	D1
Pertuzumab Monoclonal antibody (anti-HER2, dimerisation domain)	840 mg loading then 420 mg	IV	D1

Cycles

docetaxel 6 or more; HP until progression

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Consider (10-20% FN risk)

Notes

Median OS 57.1 months; DESTINY-Breast09 (T-DXd + pertuzumab) now competes for first line.

Used in

HER2-positive breast cancer

Trials

CLEOPATRA DESTINY-Breast09

Products

DocetaxelTrastuzumabPertuzumab

Source

CLEOPATRA, NEJM 2012

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.